IGF-1 DES, more precisely written as des(1-3)IGF-I, is a truncated variant of insulin-like growth factor-I in which the first three N-terminal amino acids — glycine, proline, and glutamate (the "GPE" tripeptide) — have been removed, leaving a 67-residue peptide instead of the native 70-residue protein. Because the glutamate at position 3 is a key contact point for the IGF-binding proteins (IGFBPs), removing it leaves the molecule largely unable to be sequestered by IGFBPs; in cultured cells des(1-3)IGF-I is reported to be roughly 10-fold more potent than intact IGF-I at stimulating hypertrophy and proliferation (Ballard et al., 1996). This article summarizes the structural basis, mechanism, published preclinical literature, and laboratory handling of IGF-1 DES as a research compound. All information here is provided strictly for in-vitro and laboratory research use only.
What Is IGF-1 DES?
IGF-1 DES is not a wholly synthetic invention. It is a naturally occurring processed form of IGF-I that has been isolated from bovine colostrum, human brain tissue, and porcine uterus, and it is thought to arise from post-translational proteolytic cleavage of full-length IGF-I (Ballard et al., 1996). The material sold as a research peptide is a recombinant or synthetically produced equivalent of that sequence.
The cleavage event that produces des(1-3)IGF-I simultaneously releases the free GPE tripeptide, which has its own separate literature as a neuroactive fragment. In other words, one enzymatic step splits native IGF-I into two biologically distinct species: a receptor-active, binding-protein-resistant growth factor, and a small tripeptide that does not engage the IGF-1 receptor at all.
Naming and abbreviations
| Term | Meaning |
| --- | --- |
| des(1-3)IGF-I | Formal name — IGF-I missing residues 1–3 |
| IGF-1 DES, DES(1-3) | Common shorthand in research-supply catalogs |
| Destripeptide IGF-1 | Older literature usage |
| GPE | Gly-Pro-Glu, the removed N-terminal tripeptide |
Mechanism of Action
IGF-1 DES binds the type 1 IGF receptor (IGF-1R) with affinity broadly comparable to native IGF-I. Its distinguishing property is not receptor affinity but binding-protein evasion.
In circulation and in culture medium, the great majority of IGF-I is bound to one of six IGFBPs, which act as a reservoir and as a brake on receptor engagement. Work from the late 1980s established that IGFBPs purified from bovine kidney (MDBK) cells strongly inhibited the ability of IGF-2 to stimulate DNA synthesis and protein accumulation in chick embryo fibroblasts, exerted an intermediate effect on IGF-1, and had essentially no inhibitory effect on des-(1-3)-IGF-1. The authors concluded that the biological potencies of the three peptides correlate inversely with how tightly they are bound by proteins released into the medium — that is, the enhanced potency of the DES variant is a consequence of it escaping the binding proteins rather than of any change at the receptor (Ross et al., 1989; reviewed in Ballard et al., 1989).
Later structure-function work localized this effect to the glutamate side chain at position 3. Its absence reduces IGFBP-3 affinity by roughly an order of magnitude or more, which is the same design logic later used in the engineered analog IGF-1 LR3, where position 3 glutamate is substituted with arginine rather than deleted.
Why this matters in cell culture
In a serum-containing or conditioned medium, cells secrete their own IGFBPs, which can make dose-response data for native IGF-I difficult to interpret — the effective free concentration is unknown and drifts over the course of an experiment. A binding-protein-resistant analog gives a more stable and reproducible relationship between the amount added and the amount available to the receptor. This is the principal reason IGF-I variants of this type appear as tool compounds in mechanistic studies.
Published Research Findings
The published literature on des(1-3)IGF-I is predominantly preclinical and concentrated in the period from the late 1980s through the 1990s, when the Adelaide group (Ballard, Francis, Wallace, Tomas, Read) characterized it in detail.
In-vitro findings
- Fibroblast and myoblast systems. Across cultured cell models, des(1-3)IGF-I was reported as approximately 10-fold more potent than IGF-I at stimulating protein accumulation, DNA synthesis, and cell hypertrophy — with the potency difference tracking IGFBP presence rather than receptor binding (Ballard et al., 1996).
- Pituitary cells. In cultured rat anterior pituitary cells, des(1-3)IGF-I was more potent than IGF-I at modulating growth hormone and IGFBP secretion, and the authors attributed the difference specifically to reduced binding by pituitary-derived IGFBPs rather than to a distinct receptor interaction (Journal of Endocrinology, 1991).
- Colon carcinoma differentiation. In human colon-carcinoma cells, des-(1-3)-IGF-I was used as a tool to mimic a putative IGF-II autocrine loop and was reported to promote differentiation of the cells — an example of the analog being used as a probe of IGF-axis signaling rather than as a growth stimulant per se (International Journal of Cancer, 1992).
Animal-model findings
Two 1991 rodent studies published in the American Journal of Physiology examined the truncated analog in models of tissue stress. In rats following gut resection, animals receiving des-(1-3)IGF-I or high-dose IGF-I gained significantly more weight and showed significantly more positive nitrogen balance than vehicle controls. In rats with surgically reduced renal mass, body weight gain, food utilization efficiency, and nitrogen balance were all increased with des-(1-3)IGF-I treatment, with the authors suggesting the improved nitrogen balance was explained at least partly by a reduced rate of muscle protein breakdown.
A recurring observation across the in-vivo literature is that the large potency advantage seen in culture is only partly retained in whole animals, and that the anabolic effects were most pronounced in gut tissue (Ballard et al., 1996). These are animal-model observations reported in the primary literature and are described here only as scientific context; they do not describe or support any use in humans.
The GPE side of the story
The tripeptide removed to create IGF-1 DES turned out to have a research life of its own. GPE does not bind the IGF-1 receptor, yet it was reported to be neuroprotective in hippocampal slices and in the immature rat brain after hypoxic–ischemic injury, apparently acting via glial cells, with an unusually wide effective concentration range and a treatment window of several hours after injury (Brain Research, 2001; reviewed by Guan & Gluckman, British Journal of Pharmacology, 2009). That line of work eventually produced the synthetic GPE analog trofinetide, which received FDA approval in March 2023 as the first drug specifically indicated for Rett syndrome (Keam, Drugs, 2023). That approval concerns a defined patient population and a different molecule; it is noted here purely as background on the biology of the IGF-I N-terminus.
IGF-1 DES vs. IGF-1 LR3
Both are IGFBP-evading IGF-I analogs, but they solve the problem differently.
| Feature | IGF-1 DES | IGF-1 LR3 |
| --- | --- | --- |
| Modification | Deletion of residues 1–3 (Gly-Pro-Glu) | Glu3→Arg substitution plus a 13-residue N-terminal extension |
| Length | 67 residues | 83 residues |
| Origin | Naturally occurring cleavage product | Engineered recombinant analog |
| Basis of reduced IGFBP binding | Loss of the Glu3 contact | Substitution at position 3 |
| Typical documented lab role | Probe of IGFBP-dependent signaling; comparator in IGF potency studies | Serum-free cell-culture supplement; IGF-1R signaling tool |
Neither is interchangeable with the other in an experimental design, and published potency comparisons depend heavily on the IGFBP content of the specific system being used.
Handling and Storage
IGF-1 DES is typically supplied as a lyophilized (freeze-dried) powder. Store lyophilized material at -20°C, protected from light and moisture; for long-term storage, -80°C is preferable. IGF-family peptides are commonly reconstituted in dilute acetic acid or another compatible acidic buffer per established laboratory protocols, with subsequent dilution into culture medium immediately before use.
Aliquot reconstituted stock into single-use volumes to avoid repeated freeze-thaw cycles, which degrade peptide integrity and reduce measurable activity. Because the defining property of this analog is its interaction (or lack of interaction) with binding proteins, investigators should record the IGFBP content of their medium and any serum supplementation, since these variables materially affect observed potency. Verify identity and purity against the certificate of analysis before use.
Freshness Note (2026)
As of 2026, des(1-3)IGF-I remains a research reagent only. No human therapeutic based on the truncated IGF-I variant has been approved in any jurisdiction, and the compound's core characterization literature still dates largely to the 1989–1996 period. The active frontier of research on the IGF-I N-terminus has shifted to the released GPE fragment and its cyclic metabolite cyclic glycine-proline (cGP) — including the 2023 approval of the GPE analog trofinetide — rather than to the truncated growth factor itself. This article was last updated in August 2026.
Conclusion
IGF-1 DES is a naturally occurring truncated form of IGF-I whose enhanced in-vitro potency is explained almost entirely by its escape from IGF-binding proteins rather than by any gain in receptor affinity. Its documented value is as a mechanistic probe of the IGF axis, particularly in systems where endogenous IGFBP secretion confounds dose-response measurement. This product is for laboratory research use only and is not intended for human or animal consumption, or for diagnostic or therapeutic use.
Frequently Asked Questions
What does "DES" mean in IGF-1 DES?
"DES" is short for "des(1-3)" — a standard chemistry prefix meaning that something has been removed. Here, the first three amino acids of IGF-I (Gly-Pro-Glu) are absent, giving a 67-residue peptide instead of the native 70-residue protein.
Why is IGF-1 DES more potent than IGF-I in cell culture?
Because it escapes the IGF-binding proteins. The glutamate at position 3 is a key IGFBP contact; without it, far less of the peptide is sequestered, so more remains free to engage the type 1 IGF receptor. Published work found that purified binding proteins inhibited IGF-1 and IGF-2 activity in fibroblast assays but did not inhibit des-(1-3)-IGF-1 (Ross et al., 1989). Reported potency differences are approximately 10-fold in cultured cells (Ballard et al., 1996).
Is IGF-1 DES naturally occurring or purely synthetic?
Both descriptions apply. The sequence occurs naturally and has been isolated from bovine colostrum, human brain, and porcine uterus, where it appears to result from post-translational cleavage of IGF-I. Research-grade material is produced recombinantly or synthetically to match that sequence.
How does IGF-1 DES differ from IGF-1 LR3?
IGF-1 DES achieves IGFBP resistance by deleting residues 1–3; IGF-1 LR3 achieves it by substituting arginine for glutamate at position 3 and adding a 13-residue N-terminal extension. DES is shorter than native IGF-I; LR3 is longer.
What happened to the three amino acids that were removed?
The released tripeptide, Gly-Pro-Glu (GPE), is itself biologically active but does not bind the IGF-1 receptor. It has been studied as a neuroprotective agent in animal models of hypoxic–ischemic brain injury, and a synthetic GPE analog, trofinetide, was approved by the FDA in 2023 for Rett syndrome.
Is IGF-1 DES approved for any human use?
No. As of 2026 there is no approved human therapeutic based on des(1-3)IGF-I anywhere. It is sold and handled strictly as a research-use-only laboratory reagent.
Research Use Only. All products and information on this page are intended for in-vitro laboratory research and further scientific investigation only. They are not drugs, foods, cosmetics, or medical devices, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. No statement here should be interpreted as a recommendation for administration to humans or animals.